Jyong Biotech Ltd. (MENS)

$10.11 -4.89 (-32.60%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,440,831
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Industry: Biotechnology
Sector: Healthcare
Phone: 886 2 2732 5205
Address:
No. 95, Xintai 5th Road, 23F-3 Section 1 Xizhi District, New Taipei City, Taiwan
topstockalerts
topstockalerts Feb. 23 at 9:23 PM
Top Gainers PT2 $VNDA $INVZW $CETY $MENS $ASPS
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 8:53 PM
$MENS can it push higher in AH?
0 · Reply
Stackdoe101
Stackdoe101 Feb. 23 at 8:51 PM
$MENS
0 · Reply
char13
char13 Feb. 23 at 8:37 PM
$MENS another runner that seems to be surprising
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 8:20 PM
$MENS Watching for the next breakout leg 👀. Price is holding tight near highs. That usually leads to expansion.
0 · Reply
coiler123
coiler123 Feb. 23 at 8:19 PM
$MENS The IPO was $7.50 so good luck they also are seeking a share issue $.
1 · Reply
topstockalerts
topstockalerts Feb. 23 at 7:51 PM
Top Gainers PT2 $EZRA $KLTO $GNPX $MENS $NCI
0 · Reply
char13
char13 Feb. 23 at 7:28 PM
$MENS another runner
0 · Reply
aquira
aquira Feb. 23 at 7:20 PM
$MENS people need to go onboard as early as now. We might go back to $20-$30 which is the fair value
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 7:12 PM
$MENS consumer Apparel turnaround angle tied to distribution footprint and gross margin recovery. Inventory discipline and DTC traction are what matter next.
0 · Reply
Latest News on MENS
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Feb 12, 2026, 8:30 AM EST - 11 days ago

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jan 30, 2026, 8:30 AM EST - 24 days ago

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech Responds to Share Price and Volume Movement

Dec 19, 2025, 9:00 AM EST - 2 months ago

Jyong Biotech Responds to Share Price and Volume Movement

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Dec 4, 2025, 8:30 AM EST - 2 months ago

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Nov 24, 2025, 8:30 AM EST - 3 months ago

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Nov 20, 2025, 8:30 AM EST - 3 months ago

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Sep 29, 2025, 8:30 AM EDT - 5 months ago

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Sep 18, 2025, 8:30 AM EDT - 5 months ago

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Sep 16, 2025, 8:18 AM EDT - 5 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Aug 22, 2025, 9:00 AM EDT - 6 months ago

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain

Jul 26, 2025, 8:00 AM EDT - 7 months ago

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jul 22, 2025, 10:40 AM EDT - 7 months ago

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

Jun 22, 2025, 4:20 PM EDT - 8 months ago

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

ALAB ARM CAI EGG IPO IPOS JCAP

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jun 18, 2025, 5:20 PM EDT - 8 months ago

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Jun 16, 2025, 11:38 PM EDT - 8 months ago

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle

Feb 10, 2025, 3:42 PM EST - 1 year ago

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle

Jyong Biotech Ltd. Begins U.S. IPO Rollout

Aug 18, 2023, 2:44 PM EDT - 2 years ago

Jyong Biotech Ltd. Begins U.S. IPO Rollout

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Aug 17, 2023, 3:16 PM EDT - 2 years ago

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Jyong Biotech IPO Registration Document (F-1)

Aug 17, 2023, 1:40 PM EDT - 2 years ago

Jyong Biotech IPO Registration Document (F-1)

topstockalerts
topstockalerts Feb. 23 at 9:23 PM
Top Gainers PT2 $VNDA $INVZW $CETY $MENS $ASPS
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 8:53 PM
$MENS can it push higher in AH?
0 · Reply
Stackdoe101
Stackdoe101 Feb. 23 at 8:51 PM
$MENS
0 · Reply
char13
char13 Feb. 23 at 8:37 PM
$MENS another runner that seems to be surprising
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 8:20 PM
$MENS Watching for the next breakout leg 👀. Price is holding tight near highs. That usually leads to expansion.
0 · Reply
coiler123
coiler123 Feb. 23 at 8:19 PM
$MENS The IPO was $7.50 so good luck they also are seeking a share issue $.
1 · Reply
topstockalerts
topstockalerts Feb. 23 at 7:51 PM
Top Gainers PT2 $EZRA $KLTO $GNPX $MENS $NCI
0 · Reply
char13
char13 Feb. 23 at 7:28 PM
$MENS another runner
0 · Reply
aquira
aquira Feb. 23 at 7:20 PM
$MENS people need to go onboard as early as now. We might go back to $20-$30 which is the fair value
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 7:12 PM
$MENS consumer Apparel turnaround angle tied to distribution footprint and gross margin recovery. Inventory discipline and DTC traction are what matter next.
0 · Reply
char13
char13 Feb. 23 at 7:09 PM
$MENS go go go
0 · Reply
Everythingisplanned
Everythingisplanned Feb. 23 at 6:54 PM
$MENS Believe!!
1 · Reply
CarolaT
CarolaT Feb. 23 at 6:45 PM
$MENS
0 · Reply
topstockalerts
topstockalerts Feb. 23 at 5:38 PM
$MENS consumer Apparel microcap where distribution wins drive narrative shifts. Margin improvement and inventory control are core metrics. Any major retail partnership moves it. Is demand stabilizing?
0 · Reply
Noriudar
Noriudar Feb. 23 at 5:35 PM
$MENS sold, maybe no good. 20% enough
0 · Reply
MochiMeerkat
MochiMeerkat Feb. 23 at 5:12 PM
:@SqueezeSharkie operating on another level 🧠❄️ Cold vision, real substance. Not following yet? That’s on you. Free game, unreal value. 🐐 $MENS $VHUB $VVPR $EZRA <<
0 · Reply
Noriudar
Noriudar Feb. 23 at 3:13 PM
$MENS common Men!
0 · Reply
EmproX
EmproX Feb. 23 at 12:38 PM
$MENS $EDRY $COCH $MGRX ••
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 6:09 PM
$MENS Current Stock Price: $1.94 Contracts to trade: $2.5 MENS Feb 20 2026 Call Entry: $0.09 Exit: $0.16 ROI: 73% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
zonelogan
zonelogan Feb. 20 at 4:25 PM
$MENS Mensa Brands is a speculative consumer microcap. Revenue visibility is limited. Liquidity risk is high.
0 · Reply
Everythingisplanned
Everythingisplanned Feb. 19 at 4:36 AM
$MENS
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 7:12 PM
$MENS RSI: 37.35, MACD: -1.4887 Vol: 0.61, MA20: 2.23, MA50: 6.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply